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AbstrAct
Introduction: Multiple gene expression based prognostic biomarkers have been 
repeatedly identified in gastric carcinoma. However, without confirmation in an 
independent validation study, their clinical utility is limited. Our goal was to establish 
a robust database enabling the swift validation of previous and future gastric cancer 
survival biomarker candidates. 
Results: The entire database incorporates 1,065 gastric carcinoma samples, 
gene expression data.  Out of 29 established markers, higher expression of 
BECN1 (HR = 0.68, p = 1.5E-05), CASP3 (HR = 0.5, p = 6E-14), COX2 (HR = 0.72, 
p = 0.0013), CTGF (HR = 0.72, p = 0.00051), CTNNB1 (HR = 0.47, p = 4.3E-15), 
MET (HR = 0.63, p = 1.3E-05), and SIRT1 (HR = 0.64, p = 2.2E-07) correlated to 
longer OS. Higher expression of BIRC5 (HR = 1.45, p = 1E-04), CNTN1 (HR = 1.44, 
p = 3.5E- 05), EGFR (HR = 1.86, p = 8.5E-11), ERCC1 (HR = 1.36, p = 0.0012), HER2 
(HR = 1.41, p = 0.00011), MMP2 (HR = 1.78, p = 2.6E-09), PFKB4 (HR = 1.56, 
p = 3.2E-07), SPHK1 (HR = 1.61, p = 3.1E-06), SP1 (HR = 1.45, p = 1.6E-05), TIMP1 
(HR = 1.92, p = 2.2E- 10) and VEGF (HR = 1.53, p = 5.7E-06) were predictive for 
poor OS. 
Materials and Methods: We integrated samples of three major cancer research 
centers (Berlin, Bethesda and Melbourne datasets) and publicly available datasets 
with available follow-up data to form a single integrated database. Subsequently, we 
performed a literature search for prognostic markers in gastric carcinomas (PubMed, 
2012–2015) and re-validated their findings predicting first progression (FP) and 
overall survival (OS) using uni- and multivariate Cox proportional hazards regression 
analysis.
Conclusions: The major advantage of our analysis is that we evaluated all genes 
in the same set of patients thereby making direct comparison of the markers feasible. 
The best performing genes include BIRC5, CASP3, CTNNB1, TIMP-1, MMP-2, SIRT, 
and VEGF.
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INtrODUctION
Gastric cancer is one of the most common 
malignancies and displays variable incidence around 
the globe. About 90–95% of the cases are sporadic, it’s 
incidence is highest in East Asia, Central Eastern Europe, 
and approximately 75% of cases present in less developed 
countries [1]. In most developed regions, rates of stomach 
cancer have variably but uniformly declined over the 
past decades, fairly due to active surveillance methods 
in selected societies [2]. There are no solid biomarkers 
besides HER2 [3] and regular clinicopathological 
parameters predicting prognosis and response to therapy, 
and ultimately, there are no efficient therapeutic options 
available which prove to change the outcome of patients 
in a groundbreaking manner.
Following endoscopic examination and histologic 
confirmation of malignancy in the harvested biopsy, 
the basis of therapy is still removal of the tumor mass 
utilizing surgery. The 5-year survival rate for R0 surgical 
resection ranges from 30 to 50% for patients with stage 
II and from 10 to 25% for patients with stage III disease 
[4]. As these patients have a high likelihood of local and 
systemic relapse, most centers offer them systemic therapy 
forming the other cornerstone of the treatment. In addition, 
radiation therapy has proved to improve 5-year survival in 
resectable tumors [5]. 
Applied prognostic factors of gastric cancer are 
limited to the clinicopathological properties in the 
routine setting today, and classically include the WHO 
histopathological type, Lauren-Järvi classification, size 
of the tumor, grade, invasion through the gastric wall 
(pT), vascular invasion, lymph node involvement (pN), 
etiological background (EBV or Helicobacter pylori) and 
HER2 overexpression [2, 5–7]. Biomarkers for diagnosis 
and prognosis of gastric cancer that have previously been 
identified are mostly non tumor tissue based, and include 
carcinoembryonic antigen (CEA), CA 125, CA 19–9, CA 
72–4 and alpha-fetoprotein [6, 8], serum pepsinogen I, 
and proteases (pepsinogen C, plasminogen activator, 
matrix metalloproteinases and their inhibitors) [9]. 
Cadherins, mucins and CD44 splicing variants are related 
to invasion/metastasis and extracellular matrix adhesion 
and degradation [7].
Among tissue based markers, overexpression 
of human epidermal growth factor receptor 2 (HER2) 
has been identified as a negative prognostic factor [7]. 
Trastuzumab with chemotherapy in HER2-positive 
advanced gastric cancer was investigated in the ToGA 
study. In this phase 3 trial, 22% of advanced stage 
cancers overexpressed HER2 and overall survival 
with trastuzumab was 2.7 months longer (hazard ratio, 
HR = 0.74, P = 0.0046) [10]. In addition, trastuzumab 
improved all of the secondary end points as well. 
In a search for robust cancer tissue related 
biomarkers, first we intended to perform a literature 
review and identify previously described markers for 
gastric cancer outcome. We merged transcriptomic data of 
multiple independent datasets to enable a cross-validation 
of these in a uniform independent cohort. We used uni- 
and multivariate analyses to assess the prognostic potential 
for each of the candidate markers. Finally, we compared 
expression in normal and gastric cancer samples to 
evaluate the change of the gene expression during tumor 
formation.
rEsULts
Database setup
The entire gastric cancer database includes 
1,065 samples from seven independent datasets. Of 
these, 652 samples were measured with the Affymetrix 
Human Genome U133 Plus 2.0 Array, 145 with 
the Human Genome U133A 2.0 Array and 268 with 
the Human Genome U133A Array. Five arrays did not 
pass quality control and were excluded from the cross-
validation analysis (all five arrays originated in the 
Bethesda dataset).
Gender and stage were available for most patients 
–70% of samples were male and stage III was most 
common (Figure 1A). Additional clinical parameters 
including TNM stages, histology and systemic treatment 
were available for about half the patients – the aggregate 
clinical characteristics are summarized in Table 1. The 
median time to first progression (FP) was 18.3 months and 
the median overall survival (OS) was 28.9 months. Even 
with these numerically significant differences, the survival 
curves comparing FP and OS display minor difference 
(Figure 1B) indicating a short post-progression survival – 
in the 503 patients with a first event and a known OS, the 
median post progression survival was 9.4 months.
Of the clinical parameters, gender, differentiation 
and histology were not significantly correlated to 
overall survival. Stage (p = 5.5E-28, see Figure 1C), 
T (p = 7.9E–15), and N (p = 1.1E-19) delivered high 
significance while there were not sufficient events 
to compute correlation to OS for M. Similar results 
were delivered for FP survival (stage: p = 1.7E-31, 
T: p = 9.2E-14, and N: p = 4.3E-20). In addition, M was 
also significant for FP (p = 1.3E-16).
Identification of biomarker candidates
The keyword search in PubMed resulted in 775 hits, 
of which 749 were in English language, and 398 were 
published between 2012–2015. Of these, 40 publications 
were categorized as review. Following careful and critical 
evaluation, a list of 29 markers emerged (Supplementary 
Table 1). Of these candidates, one gene was not present 
on the gene chips (AFAP1L2), and the remaining 28 were 
evaluated in the cross-validation.
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Table 1: Summary of aggregate clinicopathological data for all patient samples included in the 
cross-validation
Parameter % N
Gender
Male 53.1% 566
Female 22.9% 244
No data 23.9% 255
Systemic treatment
No Adjuvant 36.9% 393
Adjuvant 22.3% 238
No data 40.8% 434
Histology (Lauren class.)
Diffuse 23.3% 248
Intestinal 31.5% 336
Mixed 3.1% 33
No data 42.1% 448
Differentiation
Poor 15.6% 166
Moderate 6.3% 67
Well 3.0% 32
No data 75.1% 800
pt
T1 1.3% 14
T2 23.8% 253
T3 19.5% 208
T4 3.7% 39
No data 51.7% 551
pN
N0 7.1% 76
N1 21.8% 232
N2 12.1% 129
N3 7.1% 76
No data 51.8% 552
cM
M0 43.1% 459
M1 5.4% 58
No data 51.5% 548
AJCC Stage
I 6.5% 69
II 13.6% 145
III 30.0% 319
IV 14.3% 152
No data 35.7% 380
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Validation of previously identified prognostic 
markers
Out of the 28 biomarkers, 19 reached significance 
level with a FDR below 5% for FP and 20 for OS in the 
univariate analysis investigating gene expression only. 
Eighteen markers were significant for both FP and OS. 
Higher expression of BECN1, CASP3, COX2, CTGF, 
CTNNB1, MET, and SIRT1 correlated to better survival. 
Higher expression of BIRC5, CNTN1, EGFR, ERCC1, 
HER2, MMP2, PFKB4, SPHK, SP1, SPARC, TIMP1 
and VEGF were predictive for poor outcome. For OS, the 
direction of correlation to survival was the same for all 
significant genes. The significant genes with hazard rates 
and p values are listed in Table 2. Supplementary Table 1. 
lists the results for all genes.
Kaplan-Meier survival plots for three of the best 
performing genes with higher expression correlated 
to better survival (CASP3, SIRT1 and CTNNB1) and 
for three of the strongest genes with higher expression 
correlating to worse survival (BIRC5, HER2 and TIMP- 1) 
are presented in Figure 2.
Multivariate analysis
When running a multivariate analysis for OS using 
all genes, BIRC5 (p = 0.0018), CASP3 (p = 2.3E-04), 
and CTNNB1 (p = 0.0011) were significant at p < 0.05. 
Marginal significance was achieved by SP1 (p = 0.07) 
and VEGF (p = 0.07). When also including stage in the 
multivariate model, only BIRC5 (p = 0.05) and stage 
(p = 1.1E-06) were significant. When including stage 
Figure 1: Database setup and clinical characteristics. List of datasets included in the database as well as basic clinical characteristics 
(A). Number of patients are given for TNM, because not all patients had these data available. Overall survival and time to first progression 
in all patients, (B) and effect of stage on overall survival (C).
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Table 2: List of significant gastric cancer genes evaluated in independent studies between 2012 and 
2015
Symbol Affy ID Gene name Ref.
First progression
HR (95% CI), p
Overall survival
HR (95% CI), p
BECN1 208946_s_at Beclin-1 [44] HR = 0.68 (0.55–0.84) p = 0.00042
HR = 0.68 (0.57–0.81) 
p = 1.5e-05
BIRC5 202094_at Survivin [25] HR = 1.52 (1.22–1.89) p = 0.00016
HR = 1.45 (1.2–1.75) 
p = 1e-04
CASP3 202763_at Caspase-3 [21] HR = 0.52 (0.42–0.64) p = 3e-10
HR = 0.5 (0.42–0.6) 
p = 6e-14
CNTN1 211203_s_at Contactin-1 [19] HR = 1.41 (1.15–1.73) p = 0.0011
HR = 1.44 (1.21–1.7) 
p = 3.5e-05
COX2 204748_at Cyclooxygenase-2 [16] HR = 0.73 (0.59–0.91) p = 0.0056
HR = 0.72 (0.59–0.88) 
p = 0.0013
CTGF 209101_at Connective tissue growth factor [22] HR = 0.71 (0.58–0.89 p = 0.0022
HR = 0.72 (0.59–0.87) 
p = 0.00051
CTNNB1 201533_at Beta-catenin [18] HR = 0.52 (0.42–0.64) p = 3.2e-10
HR = 0.47 (0.38–0.57) 
p = 4.3e-15
EGFR 201983_s_at Epidermal growth factor receptor [12]
HR = 1.85 (1.49–2.29) 
p = 1.6e-08
HR = 1.86 (1.54–2.25) 
p = 8.5e-11
ERCC1 203720_s_at Excision repair complementation group 1 [45]
HR = 1.38 (1.12–1.69) 
p = 0.002
HR = 1.36 (1.13–1.63) 
p = 0.0012
HER2 216836_s_at Human epidermal growth factor receptor 2 [46]
HR = 1.38 (1.12–1.69) 
p = 0.0021
HR = 1.41 (1.18–1.68) 
p = 0.00011
HIF1a 200989_at Hypoxia-inducible factors-1 alpha [14] n.s.
HR = 0.73 (0.62–0.87) 
p = 0.00036
MET (HGFR) 203510_at Hepatocyte growth factor receptor [47]
HR = 0.69 (0.55–0.87) 
p = 0.0018
HR = 0.63 (0.51–0.77) 
p = 1.3e-05
MMP-2 201069_at Matrix metalloproteinase 2 [24] HR = 1.64 (1.33–2.02) p = 2.8e-06
HR = 1.78 (1.47–2.16) 
p = 2.6e-09
NOV 200724_at Nephroblastoma Overexpressed [22] n.s. HR = 1.45 (1.22–1.72) p = 1.7e-05
PFKB4 206246_at 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 [48]
HR = 1.7 (1.33–2.19)  
p = 2.5e-05
HR = 1.56 (1.32–1.86) 
p = 3.2e-07
SIRT1 218878_s_at Silent mating type information regulation 1 [49]
HR = 0.56 (0.45–0.7) 
p = 1.1e-07
HR = 0.64 (0.54–0.76) 
p = 2.2e-07
SPHK1 219257_s_at Sphingosine kinase 1 [50] HR = 1.62 (1.31–1.99) p = 5.6e-06
HR = 1.61 (1.31–1.96) 
p = 3.1e-06
SP1 214732_at Specificity protein 1 [20] HR = 1.47 (1.19–1.82) p = 4e-04
HR = 1.45 (1.23–1.72) 
p = 1.6e-05
SPARC 212667_at Secreted protein acidic and rich in cysteine [51]
HR = 1.34 (1.08–1.66) 
p = 0.007 n.s.
TIMP-1 201666_at Tissue inhibitor of metalloproteinase-1 [23]
HR = 1.77 (1.42–2.22) 
p = 3.9e-07
HR = 1.92 (1.57–2.36) 
p = 2.2e-10
VEGF 210512_s_at Vascular endothelial growth factor [15]
HR = 1.75 (1.41–2.17) 
p = 2.9e-07
HR = 1.53 (1.27–1.85) 
p = 5.7e-06
Statistical test: Cox univariate regression analysis, HR: hazard rate, CI: confidence interval, n.s.: p value over the 5% FDR 
cutoff. Bold: see survival plots in Figure 2.
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and age in the multivariate model, only HIF1alpha 
(p = 0.02), SPARC (p = 0.03), stage (p = 6.8E-07), and 
age (p = 0.002) were significant.
In case of FP, when including all genes in a 
multivariate Cox regression, BIRC5 (p = 0.0017), 
CASP3 (p = 9.7E-05), CTNNB1 (p = 0.01), MMP-2 
(p = 0.0092), SIRT1 (p = 0.035), SPARC (p = 0.0024), 
and VEGF (p = 0.027) were significant at p < 0.05. 
However, when including stage or stage and age, only 
VEGF (p = 0.02), stage (p = 9.3E-07), and age (p = 0.01) 
remained significant. We have to note that the multivariate 
analysis used only a fraction of patients included in the 
univariate analysis, as not all patients had complete 
clinical annotation (n = 316 for OS and n = 240 for FP).
Correlation to proliferation and HER2 
expression
We used the expression of MKI67 as a surrogate 
of proliferation and run a Spearman correlation analysis 
for all genes. MKI67 itself had a strong prognostic value 
when examined in a univariate analysis for both overall 
survival (p = 0.0017, HR = 1.32) and relapse-free survival 
(p = 0.0015 and HR = 1.39).
Figure 2: Survival for a selected set of the best performing markers. Kaplan-Meier survival plots show that higher expression 
of CASP3, CTNNB1 and SIRT1 results in a better OS, while higher expression of BIRC5, TIMP-1 and HER2 lead to worse survival (A). 
Forest plots for CASP3, TIMP-1, and HER2 (B).
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Positive correlation to MKI67 expression was 
delivered by BIRC5 (coeff = 0.57, p < 1E-20), uPAR 
(coeff = 0.27, p = 3.9E-19), mTOR (coeff = 0.26, 
p = 1.6E- 18), SPHK1 (coeff = 0.21, p = 2.1E-12), and 
HER2 (coeff = 0.21, p = 2.8E-12). Negative correlation 
was observed for CTGF (coeff = –0.34, p = 9.6E- 31), 
SPARC (coeff = -0.31, p = 3E-25), PECAM-1 
(coeff = –0.30, p = 9.2E-24), and SIRT1 (coeff = –0.23, 
p = 1.6E-14). As higher expression of multiple genes 
with negative correlation resulted in better survival (e.g. 
CTGF, SIRT1), and higher expression of genes with 
positive correlation delivered worse survival (e.g. BIRC5, 
HER2, SP1), we computed the correlation between 
the achieved hazard rate and the correlation coefficient 
against MKI67 expression. This analysis delivered a 
borderline significance (coeff = 0.32, p = 0.04). The same 
analysis performed for HER2 identified SP1 (coeff = 0.26, 
p = 5.1E-18), BIRC5 (coeff = 0.26, p = 5.2E-18), and 
EGFR (coeff = 0.20, p = 4.9E-17) having the highest 
correlation between gene expression and HER2 expression.
Expression in non-tumor gastric tissues
The keywords “gastric” and “normal” GEO 
delivered 266 datasets. When reducing the search to 
individual platforms, nine datasets were generated 
with the GPL96, 35 datasets with the GPL570 and two 
datasets with the GPL571 platform.  Of these, five datasets 
(GSE44740, GSE51725, GSE13911, GSE43346, and 
GSE3526) contained expression data for a total of 57 
normal gastric tissue specimens.
When comparing gastric normal and tumor samples, 
of all 28 genes, 6 were significant below p < 0.01 and 
had a fold change increase over 1.5 (BIRC5, CTNNB1, 
HER2, MET, PECAM-1 and uPAR) while only one gene 
had a 1.5-fold change reduction at the same significance 
(MMP- 2). The means with 95% confidence intervals for 
these genes are presented in Figure 3.  Supplementary 
Table 2 contains all the expression values with the Mann-
Whitney p value for each gene.
DIscUssION
In this project, we performed a validation for 
previously identified biomarkers for gastric cancer outcome 
and prognosis prediction. To assemble a sizeable patient 
number, we collected data from three cancer centers around 
the globe (Europe, USA, Australia), and integrated with 
additional publicly available datasets. Then, in a literature 
search we selected 28 relevant markers from the past few 
years (2012–2015), which were disclosed to be related to 
survival of gastric adenocarcinoma. Analysis was restricted 
to the most relevant genes by assessing only markers which 
had been previously published in review manuscripts.
Most of the molecules were related to worse 
outcome, being negative prognostic factors. The significant 
genes include members of the epidermal growth factor 
family and related genes (EGFR, HER2, SP1) [11–13] , 
hypoxia-induced and angiogenic genes (HIF1A, VEGF, 
COX-2) [14–16], members of the MET and NOTCH 
signaling pathway (MET, CTNNB1, CNTN1) [17–19], 
regulators of survival and proliferation (SP1, CASP3, 
CTGF) [20–22], and genes involved in cellular motility 
(TIMP, MMP2) [23, 24]. All these genes are members 
of important pathways that contribute to progression of 
the neoplastic process through proliferation and survival 
by reprogramming the cell’s metabolism, mitochondrial 
functions, protein and lipid synthesis, cytoskeletal 
organization and signaling. 
The strongest candidate gene was BIRC5 
(baculoviral inhibitor of apoptosis repeat containing 5, 
also known as survivin) – although numerically other 
genes (like TIMP-1) reached a higher hazard rate, but 
survivin remained significant in a multivariate analysis as 
well. BIRC5 has multiple effects including inhibition of 
apoptosis, enhancing cell proliferation, and promotion of 
angiogenesis [25]. The correlation between survivin and 
gastric cancer survival was described in multiple studies 
[25, 26]. In addition to effect on survival, we observed the 
highest correlation between BIRC5 and MKI67 expression 
which supports the link between survivin expression and 
progression through the cell cycle. However, MKI67 
expression per se was not correlated to survival in our 
Cox regression analysis suggesting that the main effect 
of BIRC5 on survival is independent of cell proliferation. 
Theoretically, targeted therapy could be pursued in gastric 
cancer with siRNA, e.g. LY2181308, is investigated 
against survivin in multiple types of cancer, however 
outcome data is pending. Furthermore, immunotherapy 
may hold promise for these patients as survivin is a strong 
antigenic peptide for the T cells [27]. 
Among the most promising markers is SIRT1 (Silent 
mating type information regulation 1), a key gene in the 
progression of gastric cancer. Earlier, it’s expression was 
associated with histological type, stage, lymph node status, 
and p53 expression [28], and proliferation as measured by 
Ki-67 index [29]. It was also identified as being down-
regulated in gastric cancer and a key regulator of NFκB/
Cyclin D1 signaling and G1 phase arrest [30], offering 
a possible therapeutic intervention in biological models. 
Here, our results confirm both the association between 
high SIRT1 and better survival and the correlation between 
SIRT1 and MKI67 expression. In theory, targeting SIRT1 
can be utilized in cancer therapy, mostly cell cycle arrest 
in G1 phase showed promise in prostate cancer with 
DU145 [31].
Previously, receptor tyrosine kinase genomic 
alterations were detected in 20.6% of cases, affecting ERBB2, 
FGFR2, and MET, suggesting potential benefit from targeted 
therapy including MET-amplified gastric tumors and ERBB2 
base substitutions [32]. Temporary but durable response to 
anti-MET agents have already been described [33]. Here, we 
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observed a significant correlation between HER2 and MET 
and survival, but FGFR2 was not significant. Nevertheless, 
currently only one of the investigated genes, HER2 
expression and amplification is utilized in the routine for 
prediction of response to anti-HER2 therapy [10]. 
Interestingly, the targetable genes (by administering 
e.g. cobimetinib, trastuzumab, and ponatinib, respectively, 
against) MET, HER2, and FGFR2 also displayed the 
highest difference with a fold change of the mean 
expressions over 2 when comparing gastric normal 
and cancer samples. However, again, FGFR2 was not 
significant – the reason for this is the uneven distribution 
of FGFR2 expression resulting in almost overlapping 
median expression at the same time.
Although our database represents a wide range 
of clinical cases, the patients are still not sufficiently 
characterized and this leads to a limitation of our study. 
While HER2 is an important marker also utilized 
Figure 3: Expression change comparing normal and cancer tissue. All markers ranked by the fold change (A), MMP-2 was 
the only gene down regulated at p < 0.01 and FC < 0.66 (B). Six genes had an expression increase over 1.5 fold with a p < 0.01 (C). The 
normalized expression values are shown for each gene. p: Mann-Whitney p value comparing normal and tumor samples. Red bar: 95% 
confidence interval.
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clinically, our patient samples were collected before 
the introduction of anti-HER2 therapy. Thus, it was not 
possible to evaluate the effect of anti-HER2 therapy 
in the dataset. In the recent years, The Cancer Genome 
Atlas (TCGA) project proposed a molecular classification 
dividing gastric cancer into four subtypes [34]. We were 
also not able to validate the markers in these subtypes 
as the classification was not available for the patients 
included in the investigated datasets. 
An alternative approach for survival prediction 
would be avoiding the utilization of a pre-defined gene 
to assign patients into prognostic cohorts. Rather, a whole 
transcriptome gene expression signature could be utilized 
to select molecularly similar patients and then determine 
prognostic expectations by evaluating the clinical outcome 
for these similar patients as has been demonstrated 
recently [35]. However, no similar methodology has been 
proposed for gastric cancer, thus we have not included 
such a model in our meta-analysis.
In summary, we collected gene expression data 
sets from three institutions and merged these with public 
datasets. Then, we performed a literature review and 
validated previously described markers for gastric cancer 
outcome. The major advantage of our analysis is that we 
evaluated all genes in the same set of patients thereby 
making direct comparison of the markers feasible. The 
best performing genes include BIRC5, CASP3, CTNNB1, 
TIMP-1, MMP-2, SIRT, SPARC, and VEGF. The 
importance of pathological parameters is supported by the 
fact that only a few genes remained significant when also 
including stage and age in a multivariate analysis. 
MATERIALS AND METHODS
Identification of previously described biomarker 
candidates
We performed a literature search in PubMed (http://
www.ncbi.nlm.nih.gov/pubmed) restricted to the timeframe 
of 2012 to 2015 utilizing the keywords “gastric”, “cancer”, 
“survival”, “gene expression” and “biomarker”. To limit the 
analysis to the most promising markers we selected only 
the English language manuscripts that were categorized as 
reviews. We performed the search in November/2015, and 
then manually continued with review of the publications 
one by one. Helicobacter pylori infection as a predisposing 
factor was not analyzed as a prognostic factor of outcome 
as there was no gene expression marker directly correlated 
to the infection. We assigned unique gene identifiers for 
each gene using the HUGO Gene Nomenclature Database 
(http://www.genenames.org/).
Database setup
We assembled a gastric cancer database using 
samples measured in three different sources including 
previously partly published data at the Max Delbrück 
Center for Molecular Medicine, Berlin, Germany 
(“Berlin dataset”, published in GEO as GSE22377) [36]; 
at the Transgenic Oncogenesis and Genomics Section, 
Laboratory of Cancer Biology and Genetics, National 
Cancer Institute, Bethesda, Maryland, USA (“Bethesda 
dataset”, published in GEO as GSE14210) [37]; and 
at the Peter MacCallum Cancer Centre, Melbourne, 
Australia (“Melbourne dataset”, published in GEO as 
GSE51105) [38]. Sample collection, hybridization, and 
gene expression measurements were described previously. 
The clinical data was updated for each dataset at the end of 
2014 and we utilized in the analysis the aggregate database 
containing all samples with available follow-up data.
Publicly available datasets 
We further extended the database using gene 
expression data downloaded from GEO. For this, we 
utilized the keywords “gastric”, “cancer”, “GPL96”, and 
“GPL570” to search GEO (http://www.ncbi.nlm.nih.
gov/geo/). Only publications with available raw data, 
clinical survival information, and at least 15 patients were 
included. Affymetrix HG-U133A (GPL96) and HG-U133 
Plus 2.0 (GPL570) microarrays were considered because 
of their overlapping set of 22,277 probe sets and because 
of our datasets were also derived using these gene chips.
Database of normal gastric samples
To discriminate genes related to carcinogenesis, we 
assembled a database of normal tissues. For this, we used 
the keywords “gastric” and “normal” in GEO without any 
limitation regarding publication time or sample number 
within the study. We included only the GPL96, GPL570, 
and GPL571 platforms in the search. Samples with 
premalignant conditions such as intestinal metaplasia were 
not included as “normal”.
Statistical analyses 
The raw CEL files were MAS5 normalized in the 
R statistical environment (http://www.r-project.org) using 
the Affy Bioconductor library. Quality control for gene 
chips and control for duplicate samples were performed as 
described previously [39]. Only arrays passing the quality 
criteria were utilized. After normalization, only probes 
measured on both GPL96 and GPL570 were retained 
(n = 22,277). We subsequently performed a second scaling 
normalization to set the average expression on each chip to 
1000 to reduce batch effects [40]. Kaplan–Meier survival 
plot and the hazard ratio with 95% confidence intervals 
and log-rank P values were calculated and plotted in R 
using Bioconductor packages. False discovery rate (FDR) 
was computed to correct for multiple testing using the 
brainwaver library in R as described previously [41] – the 
FDR cutoff was set at 5%. Expression in cancerous and 
Oncotarget49331www.impactjournals.com/oncotarget
normal samples was compared using a Mann-Whitney 
U-test.
Multivariate analysis
We performed a multivariate analysis using Cox 
proportional hazards regression including the gene 
expression markers and clinical variables including stage, 
age, Lauren classification, differentiation, and gender. In 
addition to the clinical data, we also determined the HER2 
and MKI67 expression using data provided on the gene 
chips. We computed HER2 status by using the probe set 
216836_s_at and setting the cutoff for positivity at 4800 
[42]. To assess correlation to proliferation, Spearman 
correlation to MKI67 expression (probes set 212021_s_
at) was computed for each of the genes separately [43]. 
In addition, Spearman correlation was also run for HER2 
without using the dichotomization.
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